Computational Simulations Identify Pyrrolidine-2,3-Dione Derivatives as Novel Inhibitors of Cdk5/p25 Complex to Attenuate Alzheimer’s Pathology
Authors:
- Amir ZebAZAmir Zeb
- Donghwan KimDKDonghwan Kim
- Sayed Ibrar AlamSASayed Ibrar Alam
- Minky SonMSMinky Son
- Raj KumarRKRaj Kumar
- Shailima RampoguSRShailima Rampogu
- Saravanan ParameswaranSaravanan Parameswaran
- Rahul Mahadev ShelakeRahul Mahadev Shelake
- Rabia Mukhtar RanaRRRabia Mukhtar Rana
- Shraddha ParateShraddha Parate
- Jae-Yean KimJae-Yean Kim
- Keun Woo LeeKLKeun Woo Lee
Open Access
- 24 May 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (5) , 746
Abstract
Mechanistically, neurotoxic insults provoke Ca2+-mediated calpain activation, which cleaves the cytoplasmic region of membrane-embedded p35 and produces its truncated form p25. Upon physical interaction, cyclin-dependent kinase 5 (Cdk5) and p25 forms hyperactivated Cdk5/p25 complex and causes severe neuropathological aberrations including hyperphosphorylated tau-mediated neurofibrillary tangles formation, Alzheimer’s symptoms, and neuronal death. Therefore, the inhibition of Cdk5/p25 complex may relieve p-tau-mediated Alzheimer’s pathology. Herein, computational simulations have identified pyrrolidine-2,3-dione derivatives as novel inhibitors of Cdk5/p25 complex. A ligand-based pharmacophore was designed and employed as 3D query to retrieve drug-like molecules from chemical databases. By molecular docking, drug-like molecules obtaining dock score > 67.67 (Goldcore of the reference compound) were identified. Molecular dynamics simulation and binding free energy calculation retrieved four pyrrolidine-2,3-dione derivatives as novel candidate inhibitors of Cdk5/p25. The root means square deviation of Cdk5/p25 in complex with candidate inhibitors obtained an average value of ~2.15 Å during the 30 ns simulation period. Molecular interactions analysis suggested that each inhibitor occupied the ATP-binding site of Cdk5/p25 and formed stable interactions. Finally, the binding free energy estimation suggested that each inhibitor had lowest binding energy than the reference compound (−113.10 kJ/mol) to recapitulate their strong binding with Cdk5/p25. Overall, these inhibitors could mitigate tau-mediated Alzheimer’s phenotype.Keywords
This publication has 69 references indexed in Scilit:
- Molecular Basis of Differential Selectivity of Cyclobutyl-Substituted Imidazole Inhibitors against CDKs: Insights for Rational Drug DesignPLOS ONE, 2013
- GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitBioinformatics, 2013
- Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivityJournal of Medicinal Chemistry, 2013
- A Systematic Review and Meta-Analysis of Buyang Huanwu Decoction in Animal Model of Focal Cerebral IschemiaEvidence-Based Complementary and Alternative Medicine, 2013
- The role of Cdk5 in cognition and neuropsychiatric and neurological pathologyBrain Research Bulletin, 2011
- Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's MiceThe Journal of Neuroscience, 2010
- CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsGenes & Cancer, 2010
- Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cellsJournal of Clinical Investigation, 2009
- Regulation of Hippocampal and Behavioral Excitability by Cyclin-Dependent Kinase 5PLOS ONE, 2009
- A geometric approach to macromolecule-ligand interactionsJournal of Molecular Biology, 1982